Although the primary targets of BMS794833 are MET and VEGFR239, BMS794833 also inhibits the polarization of monocytes into tumor-associated macrophages through a polypharmacological effect rather than inhibition of MET and VEGFR240. This evidence concerns the gene MET and neoplasm.